A total of 3122 patients with documented coronary artery heart disease who were aged 45 to 74 years and had a total cholesterol level between 180 and 250 mg/dL , low-density lipoprotein cholesterol level < or = 180 mg/dL , a high-density lipoprotein cholesterol level < or = 45 mg/dL , a triglyceride level < or = 300 mg/dL , and a fasting glucose < or = 160 mg/dL were randomized to receive 400 mg of bezafibrate daily or placebo .
